IP Verse

Betapharm Arzneimittel patent opposition analysis

CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Latest oppositions filed by Betapharm Arzneimittel

Explore patent oppositions filed by Betapharm Arzneimittel against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Aug 21, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP4321157
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 23, 2025
EP3494972
Combinations Of Dolutegravir And Lamivudine For The Treaetment Of Hiv InfectionVIIV HEALTHCARESep 11, 2024
EP3626270
New UseNOVARTISJul 2, 2024
EP3294283
Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTISDec 7, 2023
EP2959894
S1P Receptor Modulators For Treating Multiple SclerosisNOVARTISJul 12, 2023
EP3461503
Methods Of Administering Tetrahydrobiopterin, Associated Compositions, And Methods Of MeasuringBIOMARIN PHARMACEUTICALOct 28, 2022
EP2545939
Methods Of Administering Tetrahydrobiopterin, Associated Compositions, And Methods Of MeasuringBIOMARIN PHARMACEUTICALSep 15, 2021
EP2340828
Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep InhibitorNOVARTISApr 15, 2021
EP2493466
Novel Antitumoral Use Of CabazitaxelAVENTIS PHARMAMar 31, 2021
EP3395338
Rapid Dissolution Formulation Of Cinacalcet HclAMGENDec 9, 2020

Top competitors of Betapharm Arzneimittel

Top competitors of Betapharm Arzneimittel based on patent oppositions.